Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 12, 2014, Pages 2143-2156

  Qiu, Yue ^a   Hu, Yuan ^b   Zhang, Zuo Yang ^a   Ye, Lei ^a   Xu, Fei Hong ^b   Schneider, Marion E ^c   Ma, Xue Ling ^d   Du, Yi Xin ^c   Zuo, Xian Bo ^a   Zhou, Fu Sheng ^a   Chen, Gang ^a   Xie, Xu Shi ^a   Zhang, Yan ^a   Xia, Hong Zhen ^a   Wu, Ji Feng ^a   Du, Wei Dong ^a,c  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d MVZ   (Germany)

Author keywords

CD44; Gastric cancer; Immunohistochemistry; OPN; Single nucleotide polymorphism

Indexed keywords

CD44 PROTEIN, HUMAN; HERMES ANTIGEN; OSTEOPONTIN;

ADULT; AGED; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; OSTEOPONTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS;

EID: 84925231467     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1761-9     Document Type: Article

References (56)

1. Ando T, Ishikawa T, Kato H et al (2009) Synergistic effect of HLA class II loci and cytokine gene polymorphisms on the risk of gastric cancer in Japanese patients with Helicobacter pylori infection. Int J Cancer 125:2595–2602. doi:10.1002/ijc.24666
2. Ashkar S, Weber GF, Panoutsakopoulou V et al (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860–864
3. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP (2008) The impact of microRNAs on protein output. Nature 455:64–71. doi:10.1038/nature07242
4. Bendardaf R, Algars A, Elzagheid A et al (2006) Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. Oncol Rep 16:741–746
5. Bhattacharya SD, Garrison J, Guo H, Mi Z, Markovic J, Kim VM, Kuo PC (2010) Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. Surgery 148:291–297. doi:10.1016/j.surg.2010.05.007
6. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW (1999) Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 43:269–287. doi:10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5
7. Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298. doi:10.1038/nrg775
8. Castelli EC, Moreau P, Oya e Chiromatzo A et al (2009) In silico analysis of microRNAS targeting the HLA-G 3′ untranslated region alleles and haplotypes. Hum Immunol 70:1020–1025. doi:10.1016/j.humimm.2009.07.028
9. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E (2009) Gastric cancer. Crit Rev Oncol Hematol 71:127–164. doi:10.1016/j.critrevonc.2009.01.004
10. Chen RX, Xia YH, Xue TC, Zhang H, Ye SL (2011) Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep 25:803–808. doi:10.3892/or.2010.1116
11. Conne B, Stutz A, Vassalli JD (2000) The 3′ untranslated region of messenger RNA: a molecular ‘hotspot’ for pathology? Nat Med 6:637–641. doi:10.1038/76211
12. Dai N, Bao Q, Lu A, Li J (2007) Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology 72:89–96. doi:10.1159/000111108
13. D’Alfonso S, Barizzone N, Giordano M et al (2005) Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52:539–547. doi:10.1002/art.20808
14. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107:1055–1061. doi:10.1172/JCI12980
15. Doventas A, Bilici A, Demirell F, Ersoy G, Turna H, Doventas Y (2012) Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer. Hepatogastroenterology 59:2196–2201. doi:10.5754/hge10498
16. Fisher LW, Jain A, Tayback M, Fedarko NS (2004) Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 10:8501–8511. doi:10.1158/1078-0432.CCR-04-1072
17. Fong YC, Liu SC, Huang CY et al (2009) Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64:263–270. doi:10.1016/j.lungcan.2008.09.003
18. Gerger A, Zhang W, Yang D et al (2011) Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 17:6934–6943. doi:10.1158/1078-0432.CCR-11-1180
19. Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, Ravazzolo R (2004) Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 20:87–96. doi:10.1152/physiolgenomics.00138.2004
20. Hamajima N, Naito M, Kondo T, Goto Y (2006) Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. Cancer Sci 97:1129–1138. doi:10.1111/j.1349-7006.2006.00290.x
21. Higashiyama M, Ito T, Tanaka E, Shimada Y (2007) Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 14:3419–3427. doi:10.1245/s10434-007-9564-8
22. Imano M, Satou T, Itoh T et al (2009) Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg 13:1577–1582. doi:10.1007/s11605-009-0955-y
23. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H (2002) Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 168:2096–2099
24. Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY, Shao CK (2012) Expressions of osteopontin (OPN), alphanubeta3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC). Chin J Cancer Res 24:103–108. doi:10.1007/s11670-012-0103-1
25. Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, Lunet N (2008) Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 19:689–701. doi:10.1007/s10552-008-9132-y
26. Lee PH, Shatkay H (2008) F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 36:D820–D824. doi:10.1093/nar/gkm904
27. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY (2007) Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44 V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67:2089–2097. doi:10.1158/0008-5472.CAN-06-3625
28. Lee TY, Lin JT, Wu CC et al (2013) Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J Clin Gastroenterol 47:e55–e59. doi:10.1097/MCG.0b013e31827b9325
29. Likui W, Hong W, Shuwen Z (2010) Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 14:74–81. doi:10.1007/s11605-009-1035-z
30. Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024–46030. doi:10.1074/jbc.M105132200
31. Lin F, Li Y, Cao J et al (2011) Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol Rep 38:5205–5210. doi:10.1007/s11033-010-0671-4
32. Maver A, Medica I, Salobir B, Tercelj M, Peterlin B (2009) Genetic variation in osteopontin gene is associated with susceptibility to sarcoidosis in Slovenian population. Dis Markers 27:295–302. doi:10.3233/DMA-2009-0675
33. Neumann WL, Coss E, Rugge M, Genta RM (2013) Autoimmune atrophic gastritis–pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 10:529–541. doi:10.1038/nrgastro.2013.101
34. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45. doi:10.1038/nrm1004
35. Raheja LF, Genetos DC, Yellowley CE (2008) Hypoxic osteocytes recruit human MSCs through an OPN/CD44-mediated pathway. Biochem Biophys Res Commun 366:1061–1066. doi:10.1016/j.bbrc.2007.12.076
36. Rud AK, Boye K, Oijordsbakken M et al (2013) Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 13:540. doi:10.1186/1471-2407-13-540
37. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N (1998) Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 83:1094–1101
38. Samson PS, Escovidal LA, Yrastorza SG, Veneracion RG, Nerves MY (2002) Re-study of gastric cancer: analysis of outcome. World J Surg 26:428–433. doi:10.1007/s00268-001-0243-9
39. Tang H, Wang J, Bai F et al (2008) Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest 26:60–67. doi:10.1080/07357900701519279
40. Teramoto H, Castellone MD, Malek RL, Letwin N, Frank B, Gutkind JS, Lee NH (2005) Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 24:489–501. doi:10.1038/sj.onc.1208209
41. Tolg C, Hofmann M, Herrlich P, Ponta H (1993) Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 21:1225–1229
42. Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19:333–345. doi:10.1016/j.cytogfr.2008.08.001
43. Wang Y, Yan W, Lu X et al (2011) Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avbeta3/PI3 K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90:642–648. doi:10.1016/j.ejcb.2011.03.005
44. Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor–ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509–512
45. Weber GF, Ashkar S, Cantor H (1997) Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians 109:1–9
46. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW (2002) Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62:2281–2286
47. Winder T, Ning Y, Yang D et al (2011) Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer 129:1096–1104. doi:10.1002/ijc.25787
48. Wu CY, Wu MS, Chiang EP et al (2007) Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56:782–789. doi:10.1136/gut.2006.109868
49. Wu IC, Wu MT, Chou SH et al (2008) Osteopontin expression in squamous cell cancer of the esophagus. World J Surg 32:1989–1995. doi:10.1007/s00268-008-9609-6
50. Xia HZ, Du WD, Wu Q et al (2012) E-selectin rs5361 and FCGR2A rs1801274 variants were associated with increased risk of gastric cancer in a Chinese population. Mol Carcinog 51:597–607. doi:10.1002/mc.20828
51. Xiao M, Hu S, Zhang L, Huang J, Jiang H, Cai X (2013) Polymorphisms of CD44 gene and nasopharyngeal carcinoma susceptibility in a Chinese population. Mutagenesis 28:577–582. doi:10.1093/mutage/get035
52. Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW, Fisher LW (1990) cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7:491–502
53. Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G (2012) Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer 12:477. doi:10.1186/1471-2407-12-477
54. Zhou X, Wu CY (2012) Association of CD44 polymorphisms with genetic susceptibilities and clinico-pathologic characteristics in breast cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 43:807–811
55. Ziebarth JD, Bhattacharya A, Chen A, Cui Y (2012) PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res 40:D216–D221. doi:10.1093/nar/gkr1026
56. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184:118–130. doi:10.1002/(SICI)1097-4652(200007)184:1<118:AID-JCP13>3.0.CO;2-Y